KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Cash & Current Investments (2016 - 2026)

Regeneron Pharmaceuticals (REGN) has disclosed Cash & Current Investments for 18 consecutive years, with $8.8 billion as the latest value for Q1 2026.

  • For Q1 2026, Cash & Current Investments rose 4.84% year-over-year to $8.8 billion; the TTM value through Mar 2026 reached $8.8 billion, up 4.84%, while the annual FY2025 figure was $8.6 billion, 4.52% down from the prior year.
  • Cash & Current Investments hit $8.8 billion in Q1 2026 for Regeneron Pharmaceuticals, up from $8.6 billion in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $10.8 billion in Q4 2023 and bottomed at $7.0 billion in Q3 2022.
  • Average Cash & Current Investments over 5 years is $8.8 billion, with a median of $8.8 billion recorded in 2026.
  • Year-over-year, Cash & Current Investments surged 101.23% in 2022 and then fell 23.85% in 2025.
  • Regeneron Pharmaceuticals' Cash & Current Investments stood at $7.7 billion in 2022, then surged by 40.07% to $10.8 billion in 2023, then decreased by 16.9% to $9.0 billion in 2024, then dropped by 4.52% to $8.6 billion in 2025, then rose by 1.73% to $8.8 billion in 2026.
  • According to Business Quant data, Cash & Current Investments over the past three periods came in at $8.8 billion, $8.6 billion, and $8.4 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.